CPC-201 Alzheimer's Disease Type Dementia: PET Study
Status:
Withdrawn
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effect of low and high dose CPC-201 on brain
function including cerebral acetylcholinesterase (AChE) activity measured by positron
emission tomography (PET).
Phase:
Phase 2
Details
Lead Sponsor:
Chase Pharmaceuticals Corporation Chase Pharmaceuticals Corporation, an affiliate of Allergan plc